H. Holloway

发表

Anticholinesterase activity of compounds related to geneserine tautomers. N-Oxides and 1,2-oxazines.

N. Greig, Qian-sheng Yu, XiaoXiang Zhu, 2002, Journal of medicinal chemistry.

Exendin-4 decelerates food intake, weight gain, and fat deposition in Zucker rats.

N. Greig, H. Holloway, J. Egan, 2000, Endocrinology.

Preclinical Investigation of the Topical Administration of Phenserine: Transdermal Flux, Cholinesterase Inhibition, and Cognitive Efficacy

N. Greig, D. Ingram, Qian-sheng Yu, 2007, Journal of Pharmacology and Experimental Therapeutics.

A cellular model of inflammation for identifying TNF-α synthesis inhibitors

N. Greig, Qian-sheng Yu, H. Holloway, 2009, Journal of Neuroscience Methods.

Time- and dose-dependent effects of the serotonergic agent quipazine on regional cerebral metabolism in rats

H. Holloway, U. Freo, G. Ricchieri, 1993, Brain Research.

Nicotine lowers the secretion of the Alzheimer's amyloid β-protein precursor that contains amyloid β-peptide in rat

N. Greig, V. Haroutunian, D. Ingram, 2002 .

Nicotine lowers the secretion of the Alzheimer's amyloid beta-protein precursor that contains amyloid beta-peptide in rat.

N. Greig, V. Haroutunian, D. Ingram, 2002, Journal of Alzheimer's disease : JAD.

Mohs micrographic surgery: a technique for total margin assessment in veterinary cutaneous oncologic surgery.

H. Holloway, J. Bernstein, E. Hodgin, 2006, Veterinary and comparative oncology.

Dose- and time-dependent effects of 1-(2,5-dimethoxy-4-iodophenyl)-2-aminopropane (DOI), a serotonergic 5-HT2 receptor agonist, on local cerebral glucose metabolism in awake rats

S. Rapoport, H. Holloway, U. Freo, 1991, Brain Research.

Adrenalectomy or metyrapone-pretreatment abolishes cerebral metabolic responses to the serotonin agonist 1-(2,5-dimethoxy-4-iodophenyl)-2-aminopropane (DOI) in the hippocampus

S. Rapoport, H. Holloway, U. Freo, 1992, Brain Research.

Tetrahydrofurobenzofuran cymserine, a potent butyrylcholinesterase inhibitor and experimental Alzheimer drug candidate, enzyme kinetic analysis

N. Greig, M. Kamal, Qian-sheng Yu, 2008, Journal of Neural Transmission.

Kinetics of Human Serum Butyrylcholinesterase Inhibition by a Novel Experimental Alzheimer Therapeutic, Dihydrobenzodioxepine Cymserine

N. Greig, M. Kamal, H. Holloway, 2008, Neurochemical Research.

Regional brain metabolic responsivity to the muscarinic cholinergic agonist arecoline is similar in young and aged Fischer-344 rats

N. Greig, S. Rapoport, H. Holloway, 1989, Brain Research.

Clinical pharmacokinetics of arecoline in subjects with Alzheimer's disease

N. Greig, S. Rapoport, M. Schapiro, 1996, Clinical pharmacology and therapeutics.

Delivery of human interferon-alpha to brain by transient osmotic blood-brain barrier modification in the rat.

N. Greig, S. Rapoport, H. Holloway, 1988, The Journal of pharmacology and experimental therapeutics.

A Synthetic Uric Acid Analog Accelerates Cutaneous Wound Healing in Mice

M. Mattson, Sung-Chun Tang, N. Greig, 2010, PloS one.

Exendin-4 Ameliorates Motor Neuron Degeneration in Cellular and Animal Models of Amyotrophic Lateral Sclerosis

M. Mattson, N. Greig, H. Holloway, 2012, PloS one.

The effects of GLP-1 on insulin release in young and old rats in the fasting state and during an intravenous glucose tolerance test.

H. Holloway, R. Perfetti, Y. Wang, 1997, The journals of gerontology. Series A, Biological sciences and medical sciences.

Cerebral Glucose Utilization in Rats is Not Altered by Hindlimb Restraint or by Femoral Artery and Vein Cannulation

S. Rapoport, H. Holloway, T. T. Soncrant, 1988, Journal of cerebral blood flow and metabolism : official journal of the International Society of Cerebral Blood Flow and Metabolism.

In vivo biological activity of exendin (1–30)

N. Greig, H. Holloway, R. Spencer, 2005, Endocrine.

Evidence of GLP-1-mediated neuroprotection in an animal model of pyridoxine-induced peripheral sensory neuropathy

N. Greig, H. Holloway, J. Mattison, 2007, Experimental Neurology.

The importance of the nine-amino acid C-terminal sequence of exendin-4 for binding to the GLP-1 receptor and for biological activity

N. Greig, H. Holloway, J. Egan, 2003, Regulatory Peptides.

Polyol profiles in Down syndrome. myo-Inositol, specifically, is elevated in the cerebrospinal fluid.

S. Rapoport, M. Schapiro, H. Holloway, 1995, The Journal of clinical investigation.

Preparation and Characterization of Tetrabenazine Enantiomers against Vesicular Monoamine Transporter 2.

N. Greig, Qian-sheng Yu, H. Holloway, 2010, ACS medicinal chemistry letters.

Thiothalidomides: novel isosteric analogues of thalidomide with enhanced TNF-alpha inhibitory activity.

N. Greig, Qian-sheng Yu, XiaoXiang Zhu, 2003, Journal of medicinal chemistry.

Novel anticholinesterases based on the molecular skeletons of furobenzofuran and methanobenzodioxepine.

N. Greig, J. Deschamps, Qian-sheng Yu, 2005, Journal of medicinal chemistry.

Glucagon-like peptide-1 can reverse the age-related decline in glucose tolerance in rats.

N. Greig, H. Holloway, J. Egan, 1997, The Journal of clinical investigation.

Butyrylcholinesterase: a new therapeutic target in AD treatment?

N. Greig, D. Ingram, Qian-sheng Yu, 2001 .

Chronic treatment with meta-chlorophenylpiperazine (m-CPP) alters behavioral and cerebral metabolic responses to the serotonin agonists m-CPP and quipazine but not 8-hydroxy-2(di-N-propylamino)tetralin

N. Greig, H. Holloway, U. Freo, 2005, Psychopharmacology.

Insertion of an N-Terminal 6-Aminohexanoic Acid after the 7 Amino Acid Position of Glucagon-Like Peptide-1 Produces a Long-Acting Hypoglycemic Agent.

N. Greig, H. Holloway, J. Egan, 2001, Endocrinology.

Insertion of an N-terminal 6-aminohexanoic acid after the 7 amino acid position of glucagon-like peptide-1 produces a long-acting hypoglycemic agent.

H. Holloway, J. Egan, M. Bernier, 2001, Endocrinology.

A practical conversion of natural physostigmine into the potent butyrylcholinesterase inhibitor N1,N8-bisnorcymserine

N. Greig, Qian-sheng Yu, XiaoXiang Zhu, 2000 .

Design, synthesis and biological assessment of novel N-substituted 3-(phthalimidin-2-yl)-2,6-dioxopiperidines and 3-substituted 2,6-dioxopiperidines for TNF-α inhibitory activity.

N. Greig, Qian-sheng Yu, H. Holloway, 2011, Bioorganic & medicinal chemistry.

Selective butyrylcholinesterase inhibition elevates brain acetylcholine, augments learning and lowers Alzheimer β-amyloid peptide in rodent

N. Greig, D. Ingram, Qian-sheng Yu, 2005 .

Inhibition of human acetyl- and butyrylcholinesterase by novel carbamates of (-)- and (+)-tetrahydrofurobenzofuran and methanobenzodioxepine.

N. Greig, Qian-sheng Yu, H. Holloway, 2006, Journal of Medicinal Chemistry.

Kinetics of human serum butyrylcholinesterase and its inhibition by a novel experimental Alzheimer therapeutic, bisnorcymserine.

N. Greig, M. Kamal, Qian-sheng Yu, 2006, Journal of Alzheimer's disease : JAD.

Novel p53 inactivators with neuroprotective action: syntheses and pharmacological evaluation of 2-imino-2,3,4,5,6,7-hexahydrobenzothiazole and 2-imino-2,3,4,5,6,7-hexahydrobenzoxazole derivatives.

C. Culmsee, M. Mattson, N. Greig, 2002, Journal of medicinal chemistry.

Thalidomide-based TNF-inhibitors for neurodegenerative diseases

Rogers, N. Greig, Qian-sheng Yu, 2004 .

Thalidomide-based TNF-alpha inhibitors for neurodegenerative diseases.

N. Greig, Qian-sheng Yu, XiaoXiang Zhu, 2004, Acta neurobiologiae experimentalis.

Methyl analogues of the experimental Alzheimer drug phenserine: synthesis and structure/activity relationships for acetyl- and butyrylcholinesterase inhibitory action.

N. Greig, J. Flippen-Anderson, H. Holloway, 2001, Journal of medicinal chemistry.

Synthesis of novel phenserine-based-selective inhibitors of butyrylcholinesterase for Alzheimer's disease.

N. Greig, Qian-sheng Yu, H. Holloway, 1999, Journal of medicinal chemistry.

Syntheses of tetrahydrofurobenzofurans and dihydromethanobenzodioxepines from 5-hydroxy-3-methyl-3H-benzofuran-2-one. Rearrangement and ring expansion under reductive conditions on treatment with hydrides.

N. Greig, Qian-sheng Yu, H. Holloway, 2005, The Journal of organic chemistry.

Novel Anticholinesterases Based on the Molecular Skeletons of Furobenzofuran and Methanobenzodioxepine

N. Greig, J. Deschamps, Qian-sheng Yu, 2005 .

A New Therapeutic Target in Alzheimer's Disease Treatment: Attention to Butyrylcholinesterase

Xiaoxiang Zhu, Nigel H. Greig, Donald K. Ingram, 2001, Current medical research and opinion.

Long-acting anticholinesterases for myasthenia gravis: synthesis and activities of quaternary phenylcarbamates of neostigmine, pyridostigmine and physostigmine.

N. Greig, Qian-sheng Yu, H. Holloway, 2010, Bioorganic & medicinal chemistry.

Pyridoxine-induced toxicity in rats: a stereological quantification of the sensory neuropathy

N. Greig, H. Holloway, P. Mouton, 2004, Experimental Neurology.

Methiothepin reduces glucose utilization in forebrain regions of awake rats

H. Holloway, G. Ricchieri, T. T. Soncrant, 2004, Psychopharmacology.

Arecoline-induced elevations of regional cerebral metabolism in the conscious rat

Stanley I. Rapoport, S. Rapoport, H. Holloway, 1985, Brain Research.

Assay of myo-inositol in cerebrospinal fluid and plasma by chemical ionization mass spectrometry of the hexaacetate derivative.

H. Holloway, H. Shetty, 1994, Biological mass spectrometry.

Tumor necrosis factor-α synthesis inhibitor 3,6′-dithiothalidomide attenuates markers of inflammation, Alzheimer pathology and behavioral deficits in animal models of neuroinflammation and Alzheimer’s disease

N. Greig, H. Holloway, B. Ray, 2012, Journal of Neuroinflammation.

Tumor necrosis factor-alpha synthesis inhibitor 3,6' -dithiothalidomide attenuates markers of inflammation, Alzheimer pathology and behavioral deficits in animal models of neuroinflammation and Alzheimer's disease

H. Praag, N. Greig, H. Holloway, 2012 .

Cognitive Impairments Induced by Concussive Mild Traumatic Brain Injury in Mouse Are Ameliorated by Treatment with Phenserine via Multiple Non-Cholinergic and Cholinergic Mechanisms

N. Greig, W. Wood, K. Becker, 2016, PloS one.

N. Greig, H. Holloway, B. Ray, 2012, Journal of Neuroinflammation.

Intravenous butyrylcholinesterase administration and plasma and brain levels of cocaine and metabolites in rats.

N. Greig, H. Holloway, D. Gorelick, 2005, European journal of pharmacology.

Blast traumatic brain injury–induced cognitive deficits are attenuated by preinjury or postinjury treatment with the glucagon-like peptide-1 receptor agonist, exendin-4

David Tweedie, Kevin G. Becker, Nigel H. Greig, 2016, Alzheimer's & Dementia.

Identification of Novel Small Molecule Inhibitors of Amyloid Precursor Protein Synthesis as a Route to Lower Alzheimer's Disease Amyloid-β Peptide

N. Greig, Qian-sheng Yu, H. Holloway, 2006, Journal of Pharmacology and Experimental Therapeutics.

Optimizing Drugs for Brain Action

N. Greig, D. Ingram, Qian-sheng Yu, 2001 .

Enhancing the GLP‐1 receptor signaling pathway leads to proliferation and neuroprotection in human neuroblastoma cells

M. Mattson, N. Greig, H. Holloway, 2010, Journal of neurochemistry.

Effects of fasting on ketone body concentrations in healthy men of different ages.

S. Rapoport, H. Holloway, E. London, 1986, Journal of gerontology.

Exendin-4 induced glucagon-like peptide-1 receptor activation reverses behavioral impairments of mild traumatic brain injury in mice

N. Greig, H. Holloway, Yazhou Li, 2013, AGE.

GLP-1 receptor stimulation preserves primary cortical and dopaminergic neurons in cellular and rodent models of stroke and Parkinsonism

M. Mattson, N. Greig, H. Holloway, 2009, Proceedings of the National Academy of Sciences.

GLP-1 receptor stimulation reduces amyloid-beta peptide accumulation and cytotoxicity in cellular and animal models of Alzheimer's disease.

M. Mattson, N. Greig, H. Holloway, 2010, Journal of Alzheimer's disease : JAD.

Apoptotic and behavioral sequelae of mild brain trauma in mice

N. Greig, H. Holloway, Yazhou Li, 2007, Journal of neuroscience research.

Dissociation Between the Potent β-Amyloid Protein Pathway Inhibition and Cholinergic Actions of the Alzheimer Drug Candidates Phenserine and Cymserine

N. Greig, M. Kamal, Qian-sheng Yu, 2008 .

The Experimental Alzheimer's Disease Drug Posiphen [(+)-Phenserine] Lowers Amyloid-β Peptide Levels in Cell Culture and Mice

N. Greig, Qian-sheng Yu, H. Holloway, 2007, Journal of Pharmacology and Experimental Therapeutics.

Soluble Neuroprotective Antioxidant Uric Acid Analogs Ameliorate Ischemic Brain Injury in Mice

M. Mattson, Sung-Chun Tang, N. Greig, 2007, NeuroMolecular Medicine.

The experimental Alzheimer drug phenserine: preclinical pharmacokinetics and pharmacodynamics

N. Greig, D. Ingram, H. Holloway, 2000, Acta neurologica Scandinavica. Supplementum.

Phenserine: A Selective, Long-Acting and Brain-Directed Acetylcholinesterase Inhibitor Affecting Cognition and β-APP Processing

N. Greig, V. Haroutunian, D. Ingram, 1997 .

Exendin-4 attenuates blast traumatic brain injury induced cognitive impairments, losses of synaptophysin and in vitro TBI-induced hippocampal cellular degeneration

N. Greig, H. Holloway, Yazhou Li, 2017, Scientific Reports.

The pattern of functional coupling of brain regions in the awake rat

Barry Horwitz, Stanley I. Rapoport, B. Horwitz, 1986, Brain Research.

Racemic N1-norphenserine and its enantiomers: Unpredicted inhibition of human acetyl- and butyrylcholinesterase and β-amyloid precursor protein in vitro

N. Greig, Qian-sheng Yu, H. Holloway, 2003 .

4′-Hydroxyphenylcarbamates of (3aS)-Eseroline and (3aS)-N(1)-Noreseroline: Potential Metabolites of the Alzheimer′s Anticholinesterase Drug Phenserine.

N. Greig, Qian-sheng Yu, H. Holloway, 1999 .

Synthesis of the Alzheimer drug Posiphen into its primary metabolic products (+)-N1-norPosiphen, (+)-N8-norPosiphen and (+)-N1, N8-bisnorPosiphen, their inhibition of amyloid precursor protein, α-Synuclein synthesis, interleukin-1β release, and cholinergic action.

N. Greig, M. Kamal, Qian-sheng Yu, 2013, Anti-inflammatory & anti-allergy agents in medicinal chemistry.

4′-Hydroxyphenylcarbamates of (3aS)-Eseroline and (3aS)-N(1)-Noreseroline: Potential Metabolites of the Alzheimer′s Anticholinesterase Drug Phenserine.

N. Greig, Qian-sheng Yu, H. Holloway, 1999 .

Exendin-4 attenuates blast traumatic brain injury induced cognitive impairments, losses of synaptophysin and in vitro TBI-induced hippocampal cellular degeneration

N. Greig, H. Holloway, Yazhou Li, 2017, Scientific Reports.

The cholinesterase inhibitor, phenserine, improves Morris water maze performance of scopolamine-treated rats.

N. Greig, D. Ingram, H. Holloway, 2005, Life sciences.

Reduced metabolic response of the aged rat brain to haloperidol

H. Holloway, G. Pizzolato, T. T. Soncrant, 1985, The Journal of neuroscience : the official journal of the Society for Neuroscience.

Effect of Nucleus Basalis Magnocellularis Ablation on Local Brain Glucose Utilization in the Rat: Functional Brain Reorganization

Barry Horwitz, Stanley I. Rapoport, B. Horwitz, 1992, The European journal of neuroscience.

Time Course of Pharmacodynamic and Pharmacokinetic Effects of Physostigmine Assessed by Functional Brain Imaging in Humans

P Pietrini, G. Alexander, P. Pietrini, 2000, Pharmacology Biochemistry and Behavior.

Development of molecular probes for the identification of extra interaction sites in the mid-gorge and peripheral sites of butyrylcholinesterase (BuChE). Rational design of novel, selective, and highly potent BuChE inhibitors.

Ettore Novellino, Marco Persico, Caterina Fattorusso, 2005, Journal of medicinal chemistry.

Once daily injection of exendin-4 to diabetic mice achieves long-term beneficial effects on blood glucose concentrations

Jie Zhou, N. Greig, H. Holloway, 1999, Diabetologia.

Syntheses of Aromatic Substituted6′-Thiothalidomides

N. Greig, Qian-sheng Yu, H. Holloway, 2008 .

Application of stable isotope tracer combined with mass spectrometric detection for studying myo-inositol uptake by cultured neurons from fetal mouse: effect of trisomy 16.

S. Rapoport, H. Holloway, H. Shetty, 1997, Journal of mass spectrometry : JMS.

Brain accumulation of myo-inositol in the trisomy 16 mouse, an animal model of Down's syndrome.

H. Holloway, Z. Galdzicki, H. Shetty, 1996, The Biochemical journal.

Anticholinesterase and pharmacokinetic profile of phenserine in healthy elderly human subjects.

N. Greig, H. Holloway, C. Canfield, 2005, Current Alzheimer research.

Total syntheses and anticholinesterase activities of (3aS)-N(8)-norphysostigmine, (3aS)-N(8)-norphenserine, their antipodal isomers, and other N(8)-substituted analogues.

H. Holloway, A. Brossi, X. Pei, 1997, Journal of medicinal chemistry.

Effects of Ginkgolide B and Ginkgo biloba extract on local cerebral glucose utilization in the awake adult rat

S. Rapoport, H. Holloway, Y. Lamour, 1991 .

Cerebrospinal fluid and plasma distribution of myo-inositol and other polyols in Alzheimer disease.

M. Schapiro, H. Holloway, H. Shetty, 1996, Clinical chemistry.

Identification of novel small molecule inhibitors of amyloid precursor protein synthesis as a route to lower Alzheimer's disease amyloid-beta peptide.

N. Greig, Qian-sheng Yu, H. Holloway, 2006, The Journal of pharmacology and experimental therapeutics.

Exendin-4 Decelerates Food Intake, Weight Gain, and Fat Deposition in Zucker Rats.

N. Greig, H. Holloway, J. Egan, 2000, Endocrinology.

Exendin-4 induced glucagon-like peptide-1 receptor activation reverses behavioral impairments of mild traumatic brain injury in mice

N. Greig, H. Holloway, Yazhou Li, 2012, AGE.

Insertion of an N-Terminal 6-Aminohexanoic Acid after the 7 Amino Acid Position of Glucagon-Like Peptide-1 Produces a Long-Acting Hypoglycemic Agent.

N. Greig, H. Holloway, J. Egan, 2001, Endocrinology.